로딩 중…
지수 로딩 중…
진매트릭스
109820· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,669-3.25%
2026-06-19
Price Chart
진매트릭스-38.07%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 34.04B KRW |
| Revenue | 10.67B KRW |
| Net Income | -358.0M KRW |
| Total Assets | 27.04B KRW |
| Net Assets | 17.25B KRW |
| Employees | 67 |
| Value | |
| P/B | 1.97x |
| P/S | 3.19x |
| FCF Yield | 3.60% |
| Profitability | |
| ROE | -2.08% |
| ROA | -1.32% |
| Op. Margin | -2.16% |
| Revenue Growth | 0.89% |
| Financial Health | |
| Debt Ratio | 156.73% |
| Total Debt | 3.60B KRW |
| FCF | 1.23B KRW |
| Cash | 2.17B KRW |
| Current Ratio | 4.45x |
| Performance | |
| 1Y Return | -38.07% |
| 1M Return | -20.14% |
| From 52W High | -56.48% |
| 1Y MDD | -52.82% |
| Trading | |
| Volume | 46,851 shares |
| Foreign Own. | 1.92% |
| Per Share | |
| EPS | -62 KRW |
| BPS | 864 KRW |
Company Info
Genematrix, established in 2000 and headquartered in Seongnam-si, Gyeonggi-do, was founded to develop pharmaceuticals and diagnostics using biotechnology, listing on KOSDAQ in 2009. The company develops and sells medical diagnostic reagents, including molecular diagnostics and biochemical reagents, leveraging its proprietary technologies. It is also developing vaccines and immuno-oncology therapeutics for disease prevention and treatment. Genematrix possesses multiplex testing technology through key products for diagnosing sexually transmitted infections, tuberculosis, and human papillomavirus, facilitating its expansion into global markets.